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Abstract Corticobasal syndrome (CBS) is characterised by
asymmetrical parkinsonism and cognitive impairment. The
underlying pathology varies between corticobasal degener-
ation, progressive supranuclear palsy, Alzheimer’s disease,
Creutzfeldt–Jakob disease and frontotemporal lobar degen-
eration sometimes in association with GRN mutations. A
61-year-old male underwent neurological examination,
neuropsychological assessment, MRI, and HMPAO-
SPECT at our medical centre. After his death at the age of
63, brain autopsy, genetic screening and mRNA expression
analysis were performed. The patient presented with slow
progressivewalkingdisabilities,non-fluentlanguageproblems,
behavioural changes and forgetfulness. His family history was
negative. He had primitive reflexes, rigidity of his arms and
postural instability. Later in the disease course he developed
dystonia of his left leg, pathological crying, mutism and
dysphagia.Neuropsychologicalassessmentrevealedprominent
ideomotor and ideational apraxia, executive dysfunction, non-
fluent aphasia and memory deficits. Neuroimaging showed
symmetrical predominant frontoparietal atrophy and hypoper-
fusion.Frontotemporal lobar degeneration (FTLD)-TDP type 3
pathology was found at autopsy. GRN sequencing revealed a
novel frameshift mutation c.314dup, p.Cys105fs and GRN
mRNA levels showed a 50% decrease. We found a novel
GRN mutation in a patient with an atypical (CBS) presenta-
tion with symmetric neuroimaging findings. GRN mutations
are an important cause of CBS associated with FTLD-TDP
type 3 pathology, sometimes in sporadic cases. Screening for
GRN mutations should also be considered in CBS patients
without a positive family history.
Keywords Corticobasal syndrome (CBS).Frontotemporal
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Introduction
Corticobasal syndrome (CBS) is characterised by progres-
sive asymmetric rigidity and apraxia, accompanied by
additional signs of cortical and extrapyramidal dysfunction
such as alien limb phenomenon, cortical sensory loss,
myoclonus, bradykinesia and focal dystonia unresponsive
to dopaminergic treatment (Boeve et al. 2003). Although
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underlying pathology of CBS, other neuropathological
causes, including frontotemporal lobar degeneration
(FTLD), Alzheimer’s disease (AD), progressive supra-
nuclear palsy (PSP) and Creutzfeldt–Jakob disease have
been reported (Boeve et al. 1999; Wadia and Lang 2007;
Tartaglia et al. 2010).
Although family history is usually negative in CBS (Spina
et al. 2007), a familial form has been described which can be
caused by progranulin (GRN) mutations (Wadia and Lang
2007; van Swieten and Heutink 2008). GRN mutations show
a high phenotypic variability reflected by diagnoses of
frontotemporal dementia, progressive non-fluent aphasia or
AD within the same families (Gass et al. 2006;B e c ke ta l .
2008; Le Ber et al. 2008; van Swieten and Heutink 2008;
Kelley et al. 2009). The underlying pathology of GRN
mutations is FTLD with TAR DNA-binding protein of
43 kDA (TDP-43) positive neuronal cytoplasmic and intra-
nuclear inclusions (Gass et al. 2006;W h i t w e l le ta l .2007;
Beck et al. 2008;K e l l e ye ta l .2009) which is known as
FTLD-TDP type 3 (Cairns et al. 2007).
In this report, we describe the clinical, radiological,
pathological and genetic features of a 61-year-old patient
with an initial presentation of symmetric CBS caused by a
novel GRN c.314dup mutation in the absence of a positive
family history.
Materials and Methods
Subjects
A 61-year-old male was referred to the outpatient clinic of
our neurology department. On the basis of neurological
examination, neuropsychological assessment, brain MRI
and single photon emission computed tomography with
99mTc-hexamethyl propyleneamine oxine–single-photon
emission computed tomography (SPECT), he was diag-
nosed with atypical parkinsonism with dementia. He died
from bronchopneumonia at the age of 63.
Neuropathological Analysis
Brain autopsy was performed by the Netherlands Brain
Bank according to their legal and ethical code of conduct.
Paraffin-embedded sections from all brain regions were
stained with haematoxylin and eosin, Bodian, methenamine
silver, and Congo Red. Immunostaining with antibodies for
tau (Innogenetics), ubiquitin (DAKO), β-amyloid (DAKO),
α-synuclein (Zymed Laboratories), p62 (BD Biosciences
Pharmingen), FUS (Sigma-Aldrich anti-FUS) and TDP-43
(Biotech) was performed. Neuropathological diagnosis was
made by a neuropathologist (A.J.M.R.).
Genetic Analysis
DNA was extracted from peripheral blood using the DNA
Blood Kit Special (Chemagen, Baesweiler), which is based
on DNA extraction and purification with magnetic beads
(Smit et al. 2000). All coding exons (2–13) and exon/intron
boundaries of GRN (NM_002087.2) were amplified from
genomic DNA by PCR and directly sequenced in both
strands using the ABI 3730XL automated sequencer
(Applied Biosystems, Foster City, CA). Data were analysed
using SeqScape software (version 2.6; Applied Biosystems).
mRNA Expression Analysis
Total RNA was extracted from cerebellar brain tissue using
the RNeasy Plus Mini Kit (Qiagen, Valencia, CA), and
quality and quantity was assessed on the 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA). RNA samples
were normalised to 50 ng/μl, and using 200 ng as the
template, a reverse transcription reaction was performed
using a 1:1 mix of random hexamers and oligo(dT) primers
and the SuperScript III system (Invitrogen, Carlsbad, CA).
Gene expression assays were ordered from Applied
Biosystems for GRN (Hs00963703_g1) and GAPDH
(Hs00266705_g1) as an endogenous control. Real-time
PCR was performed on an ABI 7900 using the TaqMan
method. Reactions contained 1 μl of cDNA amplified with
0.25 μl primer/probe mix and 2.5 μl TaqMan 2× Universal
PCR Master Mix (Applied Biosystems, Foster City, CA).
The cycling parameters recommended by the manufacturer
were followed. All samples were run in triplicate and
normalised to GAPDH. The carboxyfluorescein (FAM)-
fluorescent signal was analysed using the SDS2.2.2
software, and relative quantities of GRN mRNA were
determined using the ΔΔct method.
Results
Clinical, Neuropsychological and Imaging Features
A 61-year-old male barber presented with a 2-year duration
of progressive walking disability, frequent falls and diffi-
culty with rising from a chair. This motor decline was later
followed by loss of initiative, emotional lability, more
compliant behaviour and increasing forgetfulness. He made
inappropriate sexual remarks, and his speech became non-
fluent with perseverations, word-finding difficulties and
comprehension deficits. Financial matters were taken over
by his wife. Furthermore, he needed assistance for dressing
and personal hygiene and was occasionally incontinent of
urine and faeces. His symptoms were unresponsive to
galantamine and levodopa. The patient’s family history was
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the age of 72 from a stroke and his mother at the age of 53
due to liver cancer.
Initial neurological examination showed normal eye
movements, a mask-like facial expression, hypokinetic
dysarthria, positive primitive reflexes, subtle axial rigidity,
hypokinetic-rigid syndrome with cogwheeling of the upper
extremities, mildly increased tone of the lower extremities,
postural instability and impaired tandem gait.
Neuropsychological testing revealed a Mini Mental State
Examination score of 24/30 with intact orientation in time
and place. The patient was highly distractible and exhibited
sparse spontaneous speech with stuttering and persevera-
tions. Ideomotor and ideational apraxia were prominent, the
patient did not succeed in imitation, constructional tasks,
and rapid alternating hand movements. Furthermore, he had
severely impaired executive and memory functions, poor
semantic word fluency and naming deficits but intact
visuospatial functions. Neuroimaging revealed mild sym-
metrical cerebral atrophy, most prominent frontoparietal and
perisylvian on MRI and symmetrical frontoparietal hypo-
perfusion on SPECT, which is shown in Fig. 1.
The patient’s condition further declined over the subse-
quent years. Neurological examination at a follow-up visit
1 year later revealed slowed saccadic eye movements,
severe symmetrical rigidity of the upper extremities, an
increased tone with dystonic flexion posturing of the left
leg and pathological crying. Finally, he developed mutism
and dysphagia, which did not respond to amitriptyline
treatment, and he died from bronchopneumonia at the age
of 63 years.
Neuropathological Examination
Gross brain (1,327 g) examination showed mild generalised
atrophy of the cortex with atrophy of caudate nucleus and
putamen and normal pigmentation of the substantia nigra.
Microscopic examination revealed moderate to severe
neuronal loss, gliosis and spongiosis in the frontal and
parietal cortices but mild changes in the temporal cortex,
hippocampus and basal ganglia. Immunohistochemistry
showed TDP-43-positive dystrophic neurites, neurocyto-
plasmatic and intranuclear inclusions most prominent in the
second superficial layer of the frontal and parietal cortices
and to a lesser extent in the temporal cortex, hippocampus
and basal ganglia, consistent with a diagnosis of FTLD-
TDP type 3 (Fig. 2) (Cairns et al. 2007).
Genetic Analysis
After receiving the autopsy results, we screened GRN and
identified a novel c.314dup, p.Cys105fs mutation. This
frameshift mutation causes premature termination of the
coding sequence, which is likely to result in loss of function
of Granulin.
mRNA Expression Analysis
GRN mRNA expression analysis in cerebellar tissue from
this patient showed a 50% decrease in GRN mRNA levels
compared to a pathologically-confirmed normal control,
confirming the pathogenicity of the mutation.
Discussion
We described a patient with an atypical CBS presentation
with symmetrical neuroimaging findings with FTLD-TDP
type 3 pathology due to a novel c.314dup, p.Cys105fs
mutation in the absence of a positive family history.
The clinical presentation of our case showed strong
similarities with the symmetric CBD described by Hassan
et al., except for the presence of ideomotor and ideational
apraxia (Hassan et al. 2010). The symmetric rigidity and the
Fig. 1 Mild symmetric
frontoparietal atrophy on MRI
(a) and symmetric parietal
hypoperfusion on SPECT scan
(b)
356 J Mol Neurosci (2011) 45:354–358absence of alien hand phenomenon and myoclonus did not
fit with the clinical diagnosis CBS in the initial phase of the
disease (Boeve et al. 2003). Moreover, the symmetric
pattern of frontoparietal atrophy on MRI and parietal
hypoperfusion on SPECT scan was inconsistent with the
typical asymmetric distribution in CBS but was in line with
the observations in symmetric CBD (Boeve et al. 2003;
Whitwell et al. 2010a; Hassan et al. 2010). In a later stage
of the disease, our patient developed dystonia in the left leg,
which made the clinical diagnosis CBS more likely (Boeve
et al. 2003). However, we did not have the opportunity to
visualize an asymmetric pattern of atrophy, as an attempt to
obtain additional neuroimaging was unsuccessful.
The neuropathological findings of the present case were
similar to those in the case by Spina et al., which showed
TDP-43 pathology most prominent in parietal and frontal
cortex and to a lesser extent in the temporal cortex, with
involvement of the basal ganglia (Spina et al. 2007). Their
patient had a more typical CBS presentation with an alien
hand phenomenon and marked asymmetry of symptoms as
well as neuroimaging findings, which is more often seen in
CBS patients with GRN mutations (Masellis et al. 2006;
Spina et al. 2007; Benussi et al. 2008). The combination of
parkinsonism, apraxia, behavioural changes, non-fluent
speech and memory impairment in our patient could
retrospectively have indicated a GRN mutation because
these symptoms have been more frequently observed in
FTLD patients with GRN mutations (Beck et al. 2008;L e
Ber et al. 2008; Kelley et al. 2009).
The absence of a positive family history in the current
case emphasises the possibility of reduced penetrance of
GRN mutations or concealed family history due to the wide
range in onset age of GRN mutations (Gass et al. 2006;L e
Ber et al. 2007; Whitwell et al. 2007; Seelaar et al. 2008).
We only screened for GRN mutations after the observation
of FTLD-TDP type 3 pathology at autopsy. This case
therefore underlines that genetic screening should be
considered even when family history appears to be
negative. The novel GRN frameshift mutation in this patient
led to a premature stop codon and thereby to loss of
function of Granulin, which was confirmed by reduced
mRNA expression levels in the cerebellar tissue. Recent
studies have shown reduced Granulin levels in the serum of
patients with GRN mutations (Coppola et al. 2008; Ghidoni
et al. 2008; Finch et al. 2009;S l e e g e r se ta l .2009;
Schofield et al. 2010). We could not confirm this in our
patient, however, since his serum was not available.
Basedontheclinicalpresentationofthis patient,wedidnot
predict FTLD-TDP pathology. Although non-fluent aphasia
and parkinsonism can be seen in FTLD-TDP, an asymmetric
presentation and pattern of atrophy is associated with all
underlying pathologies of CBS, including CBD, PSP, FTLD
and AD (Whitwell et al. 2010a). In addition, the extension of
atrophy into the frontal cortex is typically asymmetric in
patients with CBS with FTLD-TDP pathology, including
those with GRN mutations (Whitwell et al. 2010a; Beck et al.
2008; Le Ber et al. 2008; van Swieten and Heutink 2008;
Rohrer et al. 2010; Whitwell et al. 2010b). Therefore the
Fig. 2 TDP-43-positive
dystrophic neurites in the frontal
cortex (a) a TDP-43-positive
neuronal intranuclear inclusion
in the parietal cortex (b), and
TDP-43-positive neuronal
cytoplasmatic inclusions in
hippocampus (c), and caudate
nucleus and putamen (d). Scale
bar=20 μm
J Mol Neurosci (2011) 45:354–358 357present case is unique by its atypical CBS presentation and
symmetric atrophy pattern associated with FTLD-TDP type 3
pathology with a novel GRN mutation.
To conclude, we found a novel GRN mutation in a
patient with an atypical CBS presentation with symmetric
neuroimaging findings without a positive family history.
GRN mutations are an important cause of CBS associated
with FTLD-TDP pathology. Genetic screening should also
be considered in CBS patients with a negative or concealed
family history.
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